{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.41","value":"13.5"},{"groupId":"OG001","spread":"12.82","value":"10.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEAN","populationDescription":"Safety analysis set included all participants who received at least one dose of study drug. Here \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)","title":"Time to Treatment Discontinuation/Failure Due to Toxicity","type":"SECONDARY","unitOfMeasure":"Months"}